Urginea maritima (L.) baker (Liliaceae) extract induces more cytotoxicity than standard chemotherapeutics in the A549 non-small cell lung cancer (NSCLC) cell line;Urginea maritima (L.) baker (Liliaceae) ekstresinin A549 küçük hücreli dışı akciǧer kanseri hücre hattında oluşturduǧu, standart kemoterapötiklerden daha yüksek sitotoksisite

Turkish Journal of Medical Sciences

Volumn 41, Issue 1, 2011, Pages 101-108

  Bozcuk, Hakan ^a   Özdoǧan, Mustafa ^a   Aykurt, Oktay ^a   Topçuoǧlu, Fatih ^a   Öztürk, Hasan ^a   Ekinci, Deniz ^a   Karadeniz, Asuman ^b   Mutlu, Aylin ^a   Burgucu, Durmuş ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b MEHMET AKIF ERSOY UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Cytotoxicity; MTT; Non small cell lung cancer; Urginea maritima

Indexed keywords

CISPLATIN; GEMCITABINE; METHANOL; ONION EXTRACT; SQUILL; WATER;

ANGIOSPERM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; MEDICINAL PLANT; PLANT LEAF;

EID: 83155181784     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0904-28     Document Type: Article

References (18)

1. Peto R, Chen ZM, Boreham J. Tobacco-the growing epidemic. Nat Med 1999; 5: 15.
2. Shrump DS, Nasser KA, Henscke Cl. Non-Small Cell Lung Cancer. In Cancer, Principles and Practice of Oncology, Lippincott Williams & Wilkins, Philadelphia 2005; 753-810.
3. Drugstore Museum. www.drugstoremuseum.com/sections/level_info2.php?level_id=91&level=2
4. Tunckok Y, Kozan O, Cavdar C, Guven H, Fowler J. Urginea Maritima (Squill) toxicity. J Toxicol Clin Toxicol 1995; 33: 83-6.
5. El Bahri L, Djegham M, Makhlouf M. Urginea maritima L (Squill): a poisonous plant of North Africa Vet Hum Toxicol 2000; 42: 108-10.
6. AAIC 2000 Program. www.aaic.org/01progrm2.htm
7. Iizuka M, Warashina T, Noro T. Bufadienolides and a new lignin from the bulbs of Urginea Maritima. Chem Pharm Bull 2001; 49: 282-6.
8. Benkeblia N. Free radical scavenging capacity and antioxidant properties of some selected onions and garlic extracts. Brazilian Archives of Biology and Technology 2005; 48: 753-9.
9. Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 2007; 31: 1069-71.
10. Yang Y, LC QJ, Du QY, Yang BH, Lin Rx, Wang SQ. Combined effects of cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol 2005; 11: 2491-6.
11. Cui YY, Xie H, Qi KB, He YM, Wang JF. Effects of Pinus Massoniata bark extract on cell proliferation and apoptosis of human Hepatoma BEL-7402 cells. World J Gastroenterol 2005; 11: 5277-82.
12. Yildiz M, Celik-Ozenci C, Akan S, Akan I, Sati L, Demir R et al. Zoledronic acid is synergistic with Vinblastine to induce apoptosis in a multidrug resistance protein-1 dependant way. Cell Biol Int 2006; 30: 278-82.
13. Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM. Phase 1 trial of Anvirzel in patients with refractory solid tumours. Invest New Drugs 2006; 24: 423-7.
14. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combination for advanced non- small cell lung cancer be platinum based? A meta-analysis of phase 3 randomised trials. Lung Cancer 2006; 51: 335-45.
15. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rossell R, Stahel R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a metaanalysis of survival outcomes. Lung Cancer 2005; 47: 69-80.
16. Wehland J, Henkart M, Klausner R, Sandoval IR. Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies. Proc Natl Acad Sci U S A 1983; 80: 4286-90.
17. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71: 1171-7.
18. Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 2008; 26: 1879-85.